Vials of AstraZeneca's Covishield COVID-19 vaccine before they are packaged inside a lab at Serum Institute of India, in Pune, India, on Nov. 30.Francis Mascarenhas/Reuters
The Serum Institute of India, which produces the AstraZeneca COVID-19 vaccine, will resume small exports via the global vaccine-sharing platform COVAX this month and raise it substantially by January, its head told The Telegraph.
“Our exports to COVAX will recommence again in October, initially these supplies will be small but by January 2022, once we have satisfied domestic demands – people forget that India is still a lower-middle income country – we will see large volumes go to COVAX,” Chief Executive Adar Poonawalla said.
Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.